(24/7 MARKET NEWS) – Ocean Biomedical’s (NASDAQ: OCEA) scientific co-founder, Dr. Jack A. Elias, MD, presented details of his previously published discoveries that have potential application for tumor suppression across multiple cancer pathways at the Legorreta Cancer Center’s recent meeting in Providence, including his lab’s groundbreaking work on understanding the development and progression of lung cancer, especially the role of Chitinase 3-like-1 (CHI3L1). He also shared details of his novel therapeutic discoveries that show the efficacy of monospecific and bispecific antibodies against CHI3L1 and PD-1 as therapies for non-small cell lung cancer, and glioblastoma multiforme. Ocean Biomedical is currently working to move these antibody therapeutic discoveries towards Phase 1 clinical trials.
Ocean Biomedical is trading at $6.04, up $1.31 (+35.18%), on volume of 1 million premarket shares.
Its 52-week trading range is $3.06 to $26.6015. It’s cleared several very recent resistance levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.